Choose your preferred way to stay informed of new case launches and settlement deadlines
Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." The Company stated that its "decision is based on the results of a prespecified interim analysis of the trial," following which the Syros determined that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low[.]" Following this news, Syros's stock price fell over 61% on August 13, 2024.
In order to be eligible to join the SYRS class action lawsuit, you must have incurred a loss on shares of Syros Pharmaceuticals purchased during the class period listed above.
TOP
